Department of Thoracic Surgery, Jining No. 1 People's Hospital, Jining, Shandong, China.
Eur Rev Med Pharmacol Sci. 2017 Dec;21(24):5696-5701. doi: 10.26355/eurrev_201712_14015.
The aim of this study was to evaluate whether serum miR-661 could serve as a biomarker for the diagnosis and prognosis of non-small cell lung cancer (NSCLC).
The expression of serum miR-661 was detected in 150 cases of NSCLC and 114 cases of normal healthy controls by Real-time PCR. Receiver-operating characteristic (ROC) curve analysis was applied to analyze diagnostic value of serum miR-661. The relationship between serum miR-661 expression and clinicopathological characteristics was investigated. Overall survival was analyzed using Kaplan-Meier method. Moreover, Cox proportional-hazards regression analyses were performed to determine the prognostic value of serum miR-661 in NSCLC patients.
We found that the expression of serum miR-661 was significantly upregulated in NSCLC compared with healthy controls (p < 0.01). The expression level of serum miR-661 was positively correlated with histological grade (p = 0.011), lymph node metastasis (p = 0.003), distant metastasis (p = 0.021) and clinical stage (p = 0.005). Then, ROC curve analysis showed that serum miR-661 has considerable diagnostic accuracy, with an area under the ROC curve (AUC) of 0.726 (p = 0.001). Moreover, NSCLC patients with serum miR-661 higher expression have shown significantly poorer overall survival than those with lower serum miR-661 expression (p = 0.004). Furthermore, multivariate analyses showed that serum miR-661 expression levels were an independent prognostic factor for survival in NSCLC patients.
Overall, these findings indicate that serum miR-661 may be a potential biomarker for the diagnosis and prognosis of NSCLC.
本研究旨在评估血清 miR-661 是否可作为非小细胞肺癌（NSCLC）诊断和预后的生物标志物。
采用实时 PCR 法检测 150 例 NSCLC 患者和 114 例健康对照者血清 miR-661 的表达。应用受试者工作特征（ROC）曲线分析血清 miR-661 的诊断价值。分析血清 miR-661 表达与临床病理特征的关系。采用 Kaplan-Meier 法分析总生存期。此外，采用 Cox 比例风险回归分析确定血清 miR-661 在 NSCLC 患者中的预后价值。
我们发现，与健康对照者相比，NSCLC 患者血清 miR-661 的表达明显上调（p＜0.01）。血清 miR-661 的表达水平与组织学分级（p=0.011）、淋巴结转移（p=0.003）、远处转移（p=0.021）和临床分期（p=0.005）呈正相关。然后，ROC 曲线分析显示，血清 miR-661 具有相当的诊断准确性，ROC 曲线下面积（AUC）为 0.726（p=0.001）。此外，血清 miR-661 高表达的 NSCLC 患者总生存期明显短于血清 miR-661 低表达者（p=0.004）。此外，多因素分析显示，血清 miR-661 表达水平是 NSCLC 患者生存的独立预后因素。
综上所述，这些发现表明血清 miR-661 可能是 NSCLC 诊断和预后的潜在生物标志物。
